Resmetirom

Madrigal Pharmaceuticals · MGL-3196 · VIA-3196

FollowEvery change as it happens, and a Monday email
Stage
in the US
Next date
Phase 3 trial completes
Trials
7 active
14 in total · 2 in the EU
Targets
 

What this is

How it works
Thyroid hormone receptor beta (THR-β) agonist
How it’s given
“All study medications will be administered according to their labels: • REZDIFFRA- Label weight-based dosing: * \<100 kg: 80 mg orally once daily. * ≥100 kg: 100 mg orally once daily”In the company’s words, NCT07848191 on ClinicalTrials.gov
Tested for
MASH - Metabolic Dysfunction-Associated Steatohepatitis (4 trials), NASH, Cirrhosis, Liver, Non-Alcoholic Fatty Liver Disease, NASH - Nonalcoholic Steatohepatitis, MASH, Heart Failure With Preserved Ejection Fraction (HFPEF)
Main trialPhase 4
“To determine the safety of Rezdiffra (Resmetirom) when administered alongside common prescriptions for Diabetes Metellus (Farxiga/dapagliflozin \& Actos/pioglitazone)”In the company’s words, NCT07848191 on ClinicalTrials.gov
Other names
MGL-3196 · VIA-3196 · Rezdiffra
Given with
Actos (Takeda Pharms USA), Farxiga (Astrazeneca AB)Other companies’ drugs in its trials

Other drugs for MASH - Metabolic Dysfunction-Associated Steatohepatitis

All 77 drugs for MASH - Metabolic Dysfunction-Associated Steatohepatitis

Coming up7

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

FDA approvals1

Trials14

TrialPhaseCompletesWhat it tests
Phase 4Recruiting Nov 2027 Rezdiffra® With Concomitant Therapies Commonly Used to Treat Comorbidities in Adults With MASH and F2-F3 Fibrosis
Phase 3Active, not recruiting Dec 2026 A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)
Phase 3Active, not recruiting Mar 2027 A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)
Phase 3Active, not recruiting Jan 2028 A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis
Phase 2Recruiting Aug 2028 Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH
Phase 2Recruiting Jul 2029 Study of Resmetirom in Children and Adolescents With MASH
Phase 1Recruiting Nov 2027 Resmetirom in Patients With MASH and HFpEF
Phase 3Completed 6 Jan 2023 A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease Patients
Phase 2Completed 25 Oct 2017 Phase 2 Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis (NASH)
Phase 2Completed 15 Jan 2018 Study of MGL-3196 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)
Phase 1Completed Oct 2011 Ascending Single-Dose Study to Evaluate VIA-3196 in Healthy Subjects
Phase 1Completed Oct 2015 Drug Interaction Study of MGL-3196 With Rosuvastatin and Simvastatin
Phase 1Completed 4 Aug 2021 Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control Subjects
Phase 1Completed 16 Sep 2024 A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses (6 Days) of 100 mg Resmetirom in Subjects With Severe Renal Impairment and in Matched Healthy Control Subjects With Normal Renal Function
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Resmetirom

Following is part of Solo: you see every change to Resmetirom the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in